The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Effect of Interferon Therapy on Hepatocellular Carcinogenesis in Patients With Chronic Hepatitis Type C: A Long–Term Observation Study of 1,643 Patients Using Statistical Bias Correction With Proportional Hazard Analysis
Open accessAbstract
The activity of interferon (IFN) is not elucidated from the viewpoint of cancer prevention in chronic hepatitis C patients en masse. The hepatocellular carcinogenesis rate was analyzed statistically in 1,643 patients with chronic hepatitis C: 1,191 patients with IFN therapy and 452 without IFN therapy. Hepatocellular carcinogenesis rates in the treated and untreated groups were 2.1% and 4.8% at the end of the 5th year, and 7.6% and 12.4% at the 10th year, respectively (P= .0036). Multivariate analysis showed that IFN slightly decreased the risk of carcinogenesis by 33%, compared with that of untreated patients (P= .14), adjusting for the confounding effects of age, fibrotic stage, gender, and γ–glutamyl transpeptidase (GGTP) value. Among 1,191 patients with IFN, 461 patients attained persistent loss of hepatitis C virus (HCV) RNA, and the other 145 patients retained normal alanine transaminase (ALT) values without loss of HCV RNA. The hazard of carcinogenesis in these 606 patients with persistent normal ALT with or without HCV–RNA clearance was significantly lower than that of untreated patients (hazard ratio: 0.32;P= .012) and that of the abnormal aminotransferase group. Among patients with chronic hepatitis C, IFN significantly decreased the hepatocellular carcinogenesis rate in those patients with normal or persistent low ALT values
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Treatment of Chronic Hepatitis C with Recombinant Interferon Alfa
Davis, G. L., Balart, L. A., Schiff, E. R., Lindsay, K., Bodenheimer, H. C., Perrillo, R. P., Carey, W., Jacobson, I. M., Payne, J., Dienstag, J. L., et al. (1989) · New England Journal of Medicine · doi:10.1056/nejm198911303212203 · Cited by 1,633
Recombinant Interferon Alfa Therapy for Chronic Hepatitis C
Di Bisceglie, A. M., Martin, P., Kassianides, C., Lisker-Melman, M., Murray, L., Waggoner, J., Goodman, Z., Banks, S. M., & Hoofnagle, J. H. (1989) · New England Journal of Medicine · doi:10.1056/nejm198911303212204 · Cited by 1,212
A class of rank test procedures for censored survival data
HARRINGTON, D. P., & FLEMING, T. R. (1982) · Biometrika · doi:10.1093/biomet/69.3.553 · Cited by 1,184
Risk Factors for Hepatocellular Carcinoma among Patients with Chronic Liver Disease
Tsukuma, H., Hiyama, T., Tanaka, S., Nakao, M., Yabuuchi, T., Kitamura, T., Nakanishi, K., Fujimoto, I., Inoue, A., Yamazaki, H., et al. (1993) · New England Journal of Medicine · doi:10.1056/nejm199306243282501 · Cited by 1,126
Nishiguchi, S., Kuroki, T., Nakatani, S., Morimoto, H., Takeda, T., Nakajima, S., Shiomi, S., Seki, S., Kobayashi, K., & Otani, S. (1995) · The Lancet · doi:10.1016/s0140-6736(95)91739-x · Cited by 857
Bruix, J., Calvet, X., Costa, J., Ventura, M., Bruguera, M., Castillo, R., María Barrera, J., Ercilla, G., María Sanchez-Tapias, J., Vall, M., et al. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91015-5 · Cited by 734
PREVALENCE OF ANTIBODIES TO HEPATITIS C VIRUS IN ITALIAN PATIENTS WITH HEPATOCELLULAR CARCINOMA
Colombo, M., Choo, Q. L., Del Ninno, E., Dioguardi, N., Kuo, G., Donato, M. F., Tommasini, M. A., & Houghton, M. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91016-7 · Cited by 666
Ikeda, K. (1993) · Hepatology · doi:10.1016/0270-9139(93)90505-h · Cited by 620
Self-citationIkeda, K., Saitoh, S., Koida, I., Arase, Y., Tsubota, A., Chayama, K., Kumada, H., & Kawanishi, M. (1993) · Hepatology · doi:10.1002/hep.1840180109 · Cited by 538
Self-citationTREATMENT OF ALCOHOLISM WITH A SENSITISING DRUG
Martensen-Larsen, O. (1948) · The Lancet · doi:10.1016/s0140-6736(48)91515-3 · Cited by 442
Ikeda, K., Saitoh, S., Suzuki, Y., Kobayashi, M., Tsubota, A., Koida, I., Arase, Y., Fukuda, M., Chayama, K., Murashima, N., et al. (1998) · Journal of Hepatology · doi:10.1016/s0168-8278(98)80339-5 · Cited by 428
Self-citationQuantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy
Hagiwara, H., Hayashi, N., Mita, E., Takehara, T., Kasahara, A., Fusamoto, H., & Kamada, T. (1993) · Gastroenterology · doi:10.1016/0016-5085(93)91025-d · Cited by 377
Hepatitis C virus antibodies in southern African blacks with hepatocellular carcinoma
Kew, M. C., Houghton, M., Choo, Q. L., & Kuo, G. (1990) · The Lancet · doi:10.1016/0140-6736(90)90474-j · Cited by 253
Hepatitis C-associated hepatocellular carcinoma
Hasan, F., Jeffers, L. J., De Medina, M., Reddy, R. K., Parker, T., Schiff, E. R., Houghton, M., Choo, Q., & Kuo, G. (1990) · Hepatology · doi:10.1002/hep.1840120323 · Cited by 235
Chayama, K., Saitoh, S., Arase, Y., Ikeda, K., Matsumoto, T., Sakai, Y., Kobayashi, M., Unakami, M., Morinagaa, T., & Kumada, H. (1991) · Hepatology · doi:10.1002/hep.1840130606 · Cited by 181
Self-citationYu, M. C., Yuan, J., Ross, R. K., & Govindarajan, S. (1997) · Hepatology · doi:10.1002/hep.510250141 · Cited by 72
Remission of liver fibrosis by interferon-α2b
Moreno, M. G., & Muriel, P. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00154-r · Cited by 38
Cited by
Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis
El–Serag, H. B., & Rudolph, K. L. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.061 · Cited by 5,415
Hepatocellular carcinoma in cirrhosis: Incidence and risk factors
Fattovich, G., Stroffolini, T., Zagni, I., & Donato, F. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.09.014 · Cited by 2,591
Omata, M., Cheng, A.-L., Kokudo, N., Kudo, M., Lee, J. M., Jia, J., Tateishi, R., Han, K.-H., Chawla, Y. K., Shiina, S., et al. (2017) · Hepatology International · doi:10.1007/s12072-017-9799-9 · Cited by 2,171
Natural history of hepatitis C.
Westbrook, R. H., & Dusheiko, G. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.07.012 · Cited by 1,049
Omata, M., Lesmana, L. A., Tateishi, R., Chen, P.-J., Lin, S.-M., Yoshida, H., Kudo, M., Lee, J. M., Choi, B. I., Poon, R. T. P., et al. (2010) · Hepatology International · doi:10.1007/s12072-010-9165-7 · Cited by 1,026
Metadata
- Authors
- Ikeda, K., Saitoh, S., Arase, Y., Chayama, K., Suzuki, Y., Kobayashi, M., Tsubota, A., Kobayashi, M., Nakamura, I., Murashima, N., Kumada, H., & Kawanishi, M.
- Venue
- Hepatology
- Published
- 1999-04
- Volume
- 29
- Issue
- 4
- Pages
- 1124-1130
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2022040029
- Cited by
- 467
- References
- 21
- FWCI
- 13.52
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.